The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis
Pooled result · MIS-CResult — go to the resultPooled odds ratio 0.04 95% CI 0.03–0.06Authors' conclusion
The published studies so far - mainly conducted during the Delta wave - indicate that (original strain) COVID-19 mRNA vaccines in children are safe and associated with significantly less development of MIS-C.
Study context
- Population
- Children and adolescents; studies from PubMed and Embase13 studies
- Comparison
- COVID-19 vaccination vs no vaccination
- Outcome
- Efficacy of COVID-19 vaccination in preventing MIS-C development
Methodological detailsPRISMA guidelines
- PRISMA guidelines
Pooled result
MIS-C
Pooled odds ratio
0.04
95% CI 0.03–0.06
Vaccinatedvs Unvaccinated
pooled OR 0.04 (95% CI 0.03–0.06)
As reported in the abstract
Further pooled results
MIS-C incidence after mRNA COVID-19 vaccination, children aged 12-18 years
- Reduced incidence of MIS-C after mRNA vaccination
Safety
MIS-C as an adverse effect of vaccination
- Risk much lower than the risk of MIS-C post-infection
Original publication
The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis. Pediatr Rheumatol Online J. Published 7 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →